Royalty Pharma (RPRX) Bank of America Global Healthcare Conference 2026 summary

Market landscape and competitive positioning

• Confident in market position as the largest and most competitive buyer and originator of drug royalties globally, with recent innovative deals including phase III financings and traditional royalties.

• Demand for royalty financing is increasing, with new sources from large pharma and expansion into geographies like China.

• Competition has expanded the market, making royalty transactions more mainstream and robust.

Growth drivers and strategic focus

• Core market for royalty financing is growing, with rising capital needs across biopharma, including emerging and scaling companies.

• Major growth pillars identified: pharma R&D partnerships, China as a new originations market, and maturing pipeline assets.

• Unapproved pipeline assets are beginning to deliver results, expected to become a more visible growth source.

Human resources and operational structure

• Headcount has tripled since IPO, now just over 100, with further growth focused on research and data teams.

• Recent hires include a head of AI and senior relationship managers to enhance research and deal origination.

• Structure as an ongoing business, not a fund, enables lower cost of capital and access to investment grade debt markets.